AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16861412 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine + fentanyl + clonidine
Number of subjects: 3
Study 12875806 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle (BLS) intervention that implements established recommendations
Number of subjects: 0
Study 12875806 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS intervention that implements established recommendations plus the DASH diet
Number of subjects: 0
Study 12875806 — intervention group
Group type: COMPARATOR
Intervention: Advice only standard of care group
Number of subjects: 0
Study 12875806 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle (BLS) intervention
Number of subjects: 0
Study 12875806 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS intervention plus DASH diet
Number of subjects: 0
Study 11832182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy after operation in group A
Number of subjects: 71
Study 11832182 — intervention group
Group type: COMPARATOR
Intervention: Control group B (no anticoagulation therapy)
Number of subjects: 71
Study 9443614 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN regimen: fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on days 1, 8, and 15 every 3 weeks.
Number of subjects: 38
Study 9443614 — intervention group
Group type: COMPARATOR
Intervention: SUPERFAN regimen: fluorouracil 340 mg/m2 and folinic acid 200 mg/m2 on days 1-5, doxorubicin 40 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on day 1 and again on day 5 every 4 weeks.
Number of subjects: 38
Study 8251276 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. clonidine 150 micrograms
Number of subjects: 10
Study 8251276 — intervention group
Group type: COMPARATOR
Intervention: extradural clonidine 150 micrograms
Number of subjects: 10
Study 8251276 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine (both routes)
Number of subjects: 10
Study 3953330 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment prescribed to 52 incontinent residents
Number of subjects: 82
Study 3953330 — intervention group
Group type: COMPARATOR
Intervention: Control group of 30 incontinent residents
Number of subjects: 82
Study 30869167 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2-12 mg/day
Number of subjects: 874
Study 30869167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 29516701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needle‐embedding therapy (once every other day for 20 days)
Number of subjects: 80
Study 29516701 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicines, neuromuscular electrical stimulation of the bilateral midlines of the neck and swallowing function training
Number of subjects: 80
Study 24890422 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure (HNP) suction
Number of subjects: 90
Study 24890422 — intervention group
Group type: COMPARATOR
Intervention: Normal negative pressure (NNP) suction
Number of subjects: 90
Study 22700533 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilization (VEM) within 24 hours of admittance
Number of subjects: 56
Study 22700533 — intervention group
Group type: COMPARATOR
Intervention: Mobilization between 24 and 48 hours (Control)
Number of subjects: 56
Study 20926998 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) and isokinetic muscular strengthening exercises
Number of subjects: 40
Study 20926998 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic exercises only (Control)
Number of subjects: 40
Study 17703315 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 11
Study 15237766 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 1473
Study 15237766 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (84 microg/d)
Number of subjects: 1473
Study 15237766 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1473
Study 15237766 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 1473
Study 12243439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweep gas flow at 1.60 l/min/m2 (Group 2)
Number of subjects: 30
Study 12243439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweep gas flow at 2.0 l/min/m2 (Group 3)
Number of subjects: 30
Study 12243439 — intervention group
Group type: COMPARATOR
Intervention: Sweep gas flow at 1.35 l/min/m2 (Group 1)
Number of subjects: 30
Study 9792386 — intervention group
Group type: EXPERIMENTAL
Intervention: Male/Female condom group
Number of subjects: 504
Study 9792386 — intervention group
Group type: COMPARATOR
Intervention: Male condom group
Number of subjects: 504
Study 7634883 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6'WT)
Number of subjects: 60
Study 7634883 — intervention group
Group type: COMPARATOR
Intervention: Prediction equation from group A: VO2 max = 0.006 x distance (feet) + 3.38
Number of subjects: 60
Study 2152844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d) and cholecalciferol (25 micrograms/d) supplementation
Number of subjects: 0
Study 2152844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 417361 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day
Number of subjects: 8
Study 417361 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 9.6 g/day
Number of subjects: 8
Study 417361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31939395 — intervention group
Group type: EXPERIMENTAL
Intervention: Holder method of pasteurization
Number of subjects: 48
Study 31939395 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash method of pasteurization
Number of subjects: 48
Study 31939395 — intervention group
Group type: COMPARATOR
Intervention: Control sample (before pasteurization)
Number of subjects: 48
Study 27651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed intranasal Morphine ARER
Number of subjects: 25
Study 27651506 — intervention group
Group type: COMPARATOR
Intervention: Crushed intranasal ER morphine
Number of subjects: 25
Study 27651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact Morphine ARER
Number of subjects: 25
Study 25546166 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fed state
Number of subjects: 0
Study 25546166 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fasted state
Number of subjects: 0
Study 24028593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne distractor (Hyrax)
Number of subjects: 32
Study 24028593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne distractor (transpalatal distractor - TPD)
Number of subjects: 32
Study 21237212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administered 1h before exercise (45 min, 2 W/kg of lean body mass)
Number of subjects: 14
Study 21237212 — intervention group
Group type: COMPARATOR
Intervention: Exercise without Acipimox
Number of subjects: 14
Study 21237212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administered 1h before exercise
Number of subjects: 14
Study 19217443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic (H-E) clamp with porcine or human insulin (40 mU/[m(2) min])
Number of subjects: 10
Study 19217443 — intervention group
Group type: EXPERIMENTAL
Intervention: First clamp
Number of subjects: 10
Study 19217443 — intervention group
Group type: EXPERIMENTAL
Intervention: Second clamp
Number of subjects: 10
Study 19217443 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic (H-E) clamp
Number of subjects: 10
Study 19217443 — intervention group
Group type: COMPARATOR
Intervention: Porcine vs human insulin
Number of subjects: 10
Study 15784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 300 mug, b.i.d.
Number of subjects: 25
Study 15784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 300 mug, b.i.d. plus midodrine 7.5 mg, t.i.d.
Number of subjects: 25
Study 15784036 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 25
Study 11915786 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Group C)
Number of subjects: 68
Study 11915786 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 6 mg (Group E‐6)
Number of subjects: 68
Study 11915786 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 12 mg (Group E‐12)
Number of subjects: 68
Study 10320260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (standard antiarrhythmic dose)
Number of subjects: 65
Study 10320260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 10320260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 65
Study 7722706 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (high protein and energy supplement)
Number of subjects: 0
Study 7722706 — intervention group
Group type: COMPARATOR
Intervention: Fresco (beverage with no protein and little energy)
Number of subjects: 0
Study 1779513 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinfar (20 mg)
Number of subjects: 3
Study 1779513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiazide (50 mg)
Number of subjects: 3
Study 1779513 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapriline (80 mg)
Number of subjects: 3
Study 1779513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 7240596 — intervention group
Group type: EXPERIMENTAL
Intervention: Urushiol oil injections
Number of subjects: 0
Study 7240596 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 0
Study 30074122 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind training
Number of subjects: 135
Study 30074122 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (Control)
Number of subjects: 135
Study 28864284 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesics (300 mg acetaminophen and 20 mg caffeine)
Number of subjects: 80
Study 28864284 — intervention group
Group type: COMPARATOR
Intervention: Codeine-containing analgesics (300 mg acetaminophen and 20 mg codeine)
Number of subjects: 80
Study 25261399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 % stannous fluoride gel and a crème containing 10 % CPP‐ACP applied three times daily and fluoride gel once daily
Number of subjects: 24
Study 25261399 — intervention group
Group type: COMPARATOR
Intervention: Similar crème without CPP‐ACP applied three times daily and fluoride gel once daily
Number of subjects: 24
Study 24293993 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg
Number of subjects: 12
Study 24293993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21793389 — intervention group
Group type: EXPERIMENTAL
Intervention: EA‐5 Hz
Number of subjects: 120
Study 21793389 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 21793389 — intervention group
Group type: EXPERIMENTAL
Intervention: EA‐50 Hz
Number of subjects: 120
Study 21793389 — intervention group
Group type: EXPERIMENTAL
Intervention: EA‐100 Hz
Number of subjects: 120
Study 19300039 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 130
Study 19300039 — intervention group
Group type: EXPERIMENTAL
Intervention: (89)Sr chloride
Number of subjects: 130
Study 19300039 — intervention group
Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 130
Study 19300039 — intervention group
Group type: COMPARATOR
Intervention: (153)Sm
Number of subjects: 130
Study 17498610 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIS (One Step Incontinence System)
Number of subjects: 24
Study 17498610 — intervention group
Group type: COMPARATOR
Intervention: BW (Box of Wipes)
Number of subjects: 24
Study 15026896 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 37
Study 15026896 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy
Number of subjects: 37
Study 11603873 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Study Module (HSM) in addition to regular teaching of clinical breast examination
Number of subjects: 136
Study 11603873 — intervention group
Group type: COMPARATOR
Intervention: Regular teaching alone (Control)
Number of subjects: 136
Study 11603873 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Study Module (HSM)
Number of subjects: 136
Study 9673532 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine treatment (20 mg/kg intravenously at the end of each hemodialysis session)
Number of subjects: 10
Study 8033496 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 128 (900 mg per day)
Number of subjects: 30
Study 8033496 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 128 (1800 mg per day)
Number of subjects: 30
Study 8033496 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 128 (3600 mg per day)
Number of subjects: 30
Study 8033496 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (1 gm twice a day)
Number of subjects: 30
Study 8033496 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 128
Number of subjects: 30
Study 2686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 400 micrograms
Number of subjects: 5
Study 2686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 micrograms
Number of subjects: 5
Study 2686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms
Number of subjects: 5
Study 2686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 200 micrograms
Number of subjects: 5
Study 2686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms
Number of subjects: 5
Study 2686331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1092282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride with marital therapy
Number of subjects: 0
Study 1092282 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride with minimal contact
Number of subjects: 0
Study 1092282 — intervention group
Group type: COMPARATOR
Intervention: Placebo with marital therapy
Number of subjects: 0
Study 1092282 — intervention group
Group type: COMPARATOR
Intervention: Placebo with minimal contact
Number of subjects: 0
Study 1092282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0
Study 1092282 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0
Study 30741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary implant overdentures on solitary attachments (group I)
Number of subjects: 50
Study 30741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary implant overdentures on bars (group II)
Number of subjects: 50
Study 28011037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor 400 mg every 12 h / Ivacaftor 250 mg every 12 h
Number of subjects: 1030
Study 28011037 — intervention group
Group type: COMPARATOR
Intervention: Lumacaftor/ivacaftor-treated patients
Number of subjects: 1030
Study 28011037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor 600 mg once daily / Ivacaftor 250 mg every 12 h
Number of subjects: 1030
Study 25251040 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 8
Study 25251040 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 8
Study 25251040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-ligating and conventional brackets
Number of subjects: 8
Study 24092568 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine detoxification technique (SDT)
Number of subjects: 91
Study 24092568 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone detoxification (MD)
Number of subjects: 91
Study 21654350 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg twice daily
Number of subjects: 27
Study 21654350 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 4 times daily
Number of subjects: 27
Study 21654350 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 27
Study 18093100 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 French guiding catheters
Number of subjects: 90
Study 18093100 — intervention group
Group type: COMPARATOR
Intervention: 7 French guiding catheters
Number of subjects: 90
Study 17178957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g IV)
Number of subjects: 418
Study 17178957 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (3 g IV)
Number of subjects: 418
Study 12753318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (0.5 mg/kg) given at the time of transplantation and 1 month later
Number of subjects: 17
Study 12753318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10618584 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 0
Study 10618584 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (ARB)
Number of subjects: 0
Study 10618584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 0
Study 10618584 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor alone (captopril)
Number of subjects: 0
Study 8906027 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath decompression surgery
Number of subjects: 420
Study 8906027 — intervention group
Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 420
Study 2068472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus clindamycin
Number of subjects: 316
Study 2068472 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus clindamycin
Number of subjects: 316
Study 6631616 — intervention group
Group type: EXPERIMENTAL
Intervention: interactive computer interview
Number of subjects: 108
Study 6631616 — intervention group
Group type: COMPARATOR
Intervention: face-to-face interview
Number of subjects: 108
Study 6631616 — intervention group
Group type: COMPARATOR
Intervention: self-administered questionnaire
Number of subjects: 108
Study 30109552 — intervention group
Group type: EXPERIMENTAL
Intervention: US-TAPb (group A)
Number of subjects: 100
Study 30109552 — intervention group
Group type: COMPARATOR
Intervention: No US-TAPb (group B)
Number of subjects: 100
Study 27659044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracongruent (UC) TKA
Number of subjects: 127
Study 27659044 — intervention group
Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) TKA
Number of subjects: 127
Study 25209052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school based intervention
Number of subjects: 2348
Study 25209052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2348
Study 25090856 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves
Number of subjects: 303
Study 25090856 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 303
Study 23032478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 131
Study 23032478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 19427625 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB with GA
Number of subjects: 80
Study 17697141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of aspirin
Number of subjects: 82
Study 15590859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated sleeve
Number of subjects: 42
Study 15590859 — intervention group
Group type: COMPARATOR
Intervention: Porous-coated sleeve
Number of subjects: 42
Study 15590859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant types
Number of subjects: 42
Study 12577370 — intervention group
Group type: EXPERIMENTAL
Intervention: Yizhidan (YZD)
Number of subjects: 0
Study 12577370 — intervention group
Group type: COMPARATOR
Intervention: Ritalin
Number of subjects: 0
Study 11565519 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily
Number of subjects: 590
Study 11565519 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg daily
Number of subjects: 590
Study 11565519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 11565519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined irbesartan groups
Number of subjects: 590
Study 9027668 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterials used in Hospital 1
Number of subjects: 0
Study 9027668 — intervention group
Group type: COMPARATOR
Intervention: Antibacterials used in Hospital 2
Number of subjects: 0
Study 8393509 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 25
Study 8393509 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and Methotrexate
Number of subjects: 25
Study 8393509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of oral azathioprine and methotrexate and high-dose intravenous methotrexate with leucovorin rescue
Number of subjects: 25
Study 8393509 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of active inflammation at entry into the prospective therapeutic protocol
Number of subjects: 25
Study 8393509 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete laboratory response with normalization of creatine kinase and other muscle-associated enzymes
Number of subjects: 25
Study 3034018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg once daily
Number of subjects: 76
Study 3034018 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg twice daily
Number of subjects: 76
Study 3034018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (concomitant treatment for nonresponders)
Number of subjects: 76
Study 28633534 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (n=24)
Number of subjects: 70
Study 28633534 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 70
Study 27147783 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine (PI) only
Number of subjects: 100
Study 27147783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkosol (96% ethanol, isopropanol‐30g and ortophenilphenol‐0.1g) and povidone iodide
Number of subjects: 100